Cargando…

Pre-admission use of sodium glucose transporter-2 inhibitor (SGLT-2i) may significantly improves Covid-19 outcomes in patients with diabetes: A systematic review, meta-analysis, and meta-regression

AIMS: This study aims to examine the effectiveness of using sodium glucose transporter-2 inhibitor (SGLT-2i) before hospital admission on Covid-19 outcomes in diabetic patients. METHODS: A literature search was conducted using specific keywords until October 24th, 2022 on 4 databases: Medline, Scopu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Permana, Hikmat, Audi Yanto, Theo, Ivan Hariyanto, Timotius
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier B.V. 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9731816/ https://www.ncbi.nlm.nih.gov/pubmed/36502891 http://dx.doi.org/10.1016/j.diabres.2022.110205

Ejemplares similares

Statin and outcomes of coronavirus disease 2019 (COVID-19): A systematic review, meta-analysis, and meta-regression
por: Hariyanto, Timotius I., et al.
Publicado: (2021)

Dipeptidyl peptidase 4 (DPP4) inhibitor and outcome from coronavirus disease 2019 (COVID-19) in diabetic patients: a systematic review, meta-analysis, and meta-regression
por: Hariyanto, Timotius Ivan, et al.
Publicado: (2021)

Pre-admission glucagon-like peptide-1 receptor agonist (GLP-1RA) and mortality from coronavirus disease 2019 (Covid-19): A systematic review, meta-analysis, and meta-regression
por: Hariyanto, Timotius Ivan, et al.
Publicado: (2021)

Coronavirus disease 2019 (Covid-19) outcomes in patients with sarcopenia: A meta-analysis and meta-regression
por: Siahaan, Yusak Mangara Tua, et al.
Publicado: (2022)

Epilepsy and the risk of severe coronavirus disease 2019 outcomes: A systematic review, meta-analysis, and meta-regression
por: Siahaan, Yusak Mangara Tua, et al.
Publicado: (2021)

Parkinson's disease may worsen outcomes from coronavirus disease 2019 (COVID-19) pneumonia in hospitalized patients: A systematic review, meta-analysis, and meta-regression
por: Putri, Cynthia, et al.
Publicado: (2021)

Mortality from coronavirus disease 2019 (Covid-19) in patients with schizophrenia: A systematic review, meta-analysis and meta-regression
por: Pardamean, Engelberta, et al.
Publicado: (2022)

Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta-regression
por: Musso, Giovanni, et al.
Publicado: (2020)

Does Gender Influence the Cardiovascular Benefits Observed with Sodium Glucose Co-Transporter-2 (SGLT-2) Inhibitors? A Meta-Regression Analysis
por: Mahmoud, Ahmed N., et al.
Publicado: (2016)

Authors’ response: Meta-analysis of statin and outcomes of coronavirus disease 2019 (COVID-19)
por: Hariyanto, Timotius Ivan, et al.
Publicado: (2021)

Delirium is a good predictor for poor outcomes from coronavirus disease 2019 (COVID-19) pneumonia: A systematic review, meta-analysis, and meta-regression
por: Hariyanto, Timotius Ivan, et al.
Publicado: (2021)

Sodium glucose transporter 2 (SGLT2) inhibition and ketogenesis
por: Kalra, Sanjay, et al.
Publicado: (2015)

MO33-5 The impact of chemotherapy for cancer patients with COVID-19 on severity and mortality outcomes: A meta-analysis
por: Hariyanto, Timotius I., et al.
Publicado: (2021)

Obstructive sleep apnea (OSA) and outcomes from coronavirus disease 2019 (COVID-19) pneumonia: a systematic review and meta-analysis
por: Hariyanto, Timotius Ivan, et al.
Publicado: (2021)

Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis
por: Donnan, Jennifer R, et al.
Publicado: (2019)

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis
por: Li, Hang-Long, et al.
Publicado: (2021)

Effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors on serum urate levels in patients with and without diabetes: a systematic review and meta-regression of 43 randomized controlled trials
por: Yip, Alicia Swee Yan, et al.
Publicado: (2022)

Correction to: Sodium–glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta‑analysis
por: Li, Hang-Long, et al.
Publicado: (2021)

Safety of sodium-glucose transporter 2 (SGLT-2) inhibitors in patients with type 2 diabetes: a meta-analysis of cohort studies
por: Li, Chun Xing, et al.
Publicado: (2023)

Anosmia/Hyposmia is a Good Predictor of Coronavirus Disease 2019 (COVID-19) Infection: A Meta-Analysis
por: Hariyanto, Timotius Ivan, et al.
Publicado: (2021)

The effect of sodium/glucose cotransporter 2 (SGLT2) inhibition on the urinary proteome
por: Cherney, David, et al.
Publicado: (2017)

Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide
por: Simes, Bryce C, et al.
Publicado: (2019)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Benefits Versus Risk
por: Jasleen, Bains, et al.
Publicado: (2023)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Harms or Unexpected Benefits?
por: Andreea, Munteanu Madalina, et al.
Publicado: (2023)

Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: A systematic review and meta-analysis
por: Heyward, James, et al.
Publicado: (2020)

Human immunodeficiency virus and mortality from coronavirus disease 2019: A systematic review and meta-analysis
por: Hariyanto, Timotius I., et al.
Publicado: (2021)

The Outcomes of Sodium-Glucose Co-transporter 2 Inhibitors (SGLT2I) on Diabetes-Associated Neuropathy: A Systematic Review and meta-Analysis
por: Kandeel, Mahmoud
Publicado: (2022)

Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors: Benefits in Diabetics With Cardiovascular Disease
por: Aftab, Saba, et al.
Publicado: (2020)

Sodium-glucose cotransporter 2 (SGLT2) inhibitor initiation and hepatocellular carcinoma prognosis
por: Hendryx, Michael, et al.
Publicado: (2022)

Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors in Heart Failure: An Umbrella Review
por: Roy, Raj, et al.
Publicado: (2023)

Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors and CKD: Are You a #Flozinator?
por: Krishnan, Anoushka, et al.
Publicado: (2023)

Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors on Cardiac Imaging Parameters: A Systematic Review and Meta-analysis of Randomized Controlled Trials
por: Wee, Caitlin Fern, et al.
Publicado: (2022)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review
por: Kalra, Sanjay
Publicado: (2016)

Fournier's Gangrene and Sodium-glucose Co-transporter 2(SGLT2) Inhibitors: Our Experience
por: Dass, Ashwitha S., et al.
Publicado: (2019)

Off-target Effects of Sodium-glucose Cotransporter 2 (SGLT-2) Inhibitor in Cardiovascular Disease
por: Hwang, Jiwon, et al.
Publicado: (2020)

Hepatic expression of sodium–glucose cotransporter 2 (SGLT2) in patients with chronic liver disease
por: Nakano, Dan, et al.
Publicado: (2022)

Association between viral hepatitis and increased risk of severe coronavirus disease 2019 (COVID-19) outcome: a systematic review and meta-analysis
por: Hariyanto, Timotius Ivan, et al.
Publicado: (2022)

Relationship between Phenotype Models Based on Waist Circumference and Triglyceride Levels and the Risk of Chronic Kidney Disease: A Systematic Review and Meta-analysis
por: Japar, Karunia Valeriani, et al.
Publicado: (2023)

Sodium-Glucose Cotransporter (SGLT2) inhibitors: A new Era in renovascular protection
por: Berbari, Adel E.
Publicado: (2020)

Effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta-analysis
por: Xu, Lubin, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_mi3q0aaj23a9hd00rmh4l498em